Patent News for Monday 5th May 2025

1. Failure to consider Post-filing data violates natural Justice, reiterates Calcutta High Court

... Patents Act. It clarified that Section 10(4) only requires that the invention be fully and particularly described and does not require data ...

2. Global trends in postbiotics market - Nutrition Insight

Postbiotic patents showed a 94% CAGR growth over the past four years. ISAPP's recent definition of postbiotics has been pivotal to the rise of patents ...

3. EmblemHealth Files Class Action Antitrust Against Alexion Related To Eculizumab - Patent

Enblem alleges that Alexion "defrauded a U.S. patent examiner" in order to "unlawfully procure[] a second set of five patents [following a first ...

4. Alpha Modus Reaches Settlement Agreement with Kroger in Patent Litigation

... patents covering intelligent retail display systems. "This settlement marks another important validation of the strength and enforceability of our ...

5. Firefly Neuroscience (AIFF) Achieves Multi-Fold Database, IP Portfolio, and Commercial ...

... patents; >60 current commercial users. These increases in propriety brain scans, patents and commercial sites represent greater than two-fold, three ...

6. Akums' breakthrough pregnancy nausea drug gets patent - Healthcare Radius

Akums patents breakthrough extended-release formula for pregnancy nausea. Akums focuses on innovation and operational efficiency across a wide ...

7. Reflections on the Inflation Reduction Act's Pill Penalty | Brownstein Hyatt Farber Schreck

... patents have expired or been found to be invalid or not infringed by ... That is, FDA approval of generic drugs is linked to the listed patents of the ...

8. The USPTO Is Issuing Patents Faster — Here's Why That Matters - Mondaq

Patents · PL. Patent Litigation · T. Trademarks. Related Webinars. See More · Webinar. 24 Jun 2025 | 9:00 AM. (1st Session) 2025 Global In-House ...

9. Patent Office Creates New Bar for Attorneys in Design Fields - Bloomberg Law News

... patents. These attorneys will still be required to pass the office's registration examination. Unlike utility patents, which cover how a thing is ...

10. Philips Secures Significant Victory in Patent Dispute With Indian DVD Makers - Lexology

In a significant decision by the Delhi High Court in February 2025 reinforcing the enforcement of standard essential patents (SEPs) in India, ...

11. South Korean firm patents futuristic tank - Defence Blog

South Korean firm patents futuristic tank ... South Korean defense manufacturer Hyundai Rotem has officially registered the design of its next- ...

12. The Business of Innovation: Managing IP for Results - Lexology

Today, intangible assets—including patents, proprietary data, algorithms, trademarks, and trade secrets—can represent up to 90% of a company's total ...

13. WSU ranked among 2024 top 100 U.S. universities for patents by NAI

With 14 U.S. utility patents, WSU is ranked 100 in the NAI's 2024 Top 100 U.S. Universities Granted Utility Patents list.

14. Moleculin Biotech Secures Two New U.S. Patents - TipRanks.com

These patents, extending until June 2040, cover methods of making liposomal Annamycin and its suspension, bolstering the company's efforts in ...

15. D. Mass Patent Litigation Update: March 2025 - Patent - United States - Mondaq

Because Glycosyn retained these exclusionary rights to its patents, it had standing to assert a claim for patent infringement. As to Abbott's second ...

16. Moleculin Biotech Granted Two Additional U.S. Patents For Annamycin - MarketScreener

Moleculin Biotech Inc: * MOLECULIN BIOTECH INC - GRANTED TWO ADDITIONAL U.S. PATENTS FOR ANNAMYCIN * MOLECULIN BIOTECH INC - PATENTS EXTEND UNTIL ...

17. Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

n Moleculin Biotech (MBRX) secures two new U.S. patents for Annamycin, extending protection until June 2040. Annamycin has FDA Fast Track Status ...

18. Moleculin Biotech (MBRX) Secures New Patents for Annamycin Innovation - GuruFocus

Moleculin Biotech (MBRX) has successfully obtained two new U.S. patents focusing on Annamycin, a promising drug candidate.

19. Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Both patents have a base patent term currently extending until June 2040, subject to adjustment for delays in prosecution and extension to account for ...

20. Moleculin secures two new US patents for cancer drug Annamycin - Investing.com

... patents for Annamycin, its novel drug candidate targeting certain cancers, including acute myeloid leukemia (AML) and soft tissue sarcoma lung ...

21. Moleculin Biotech announces granting of two new U.S. patents - TipRanks.com

Moleculin Biotech (MBRX) announced the U.S. Patent and Trademark Office has granted two additional U.S. patents with claims covering Annamycin.

22. Diamond Lake Minerals Launches Advanced Materials & IP Division and Files ... - Taiwan News

Intellectual Property Development - Leverage DLMI's internal R&D and external collaborations to file patents in key domains, including advanced alloys ...

23. Moleculin Biotech (MBRX) Granted Two New U.S. Patents - StreetInsider

Moleculin Biotech, Inc., (Nasdaq: MBRX) today announced the U.S. Patent and Trademark Office (USPTO) has granted two additional U.S. patents with ...

24. Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint ...

27 granted patents. >60 current commercial users; These increases in propriety brain scans, patents and commercial sites represent greater than two ...

25. Recentive Analytics v. Fox: The Federal Circuit Provides Analysis on the Patent Eligibility of ...

On April 18, 2025, the Federal Circuit remained consistent with previous Alice decisions by holding that four machine learning patents involved in ...

26. Case: Patents/Eligibility (Fed. Cir.) - Bloomberg Law News

The court affirmed the decision of a federal district court that several claims of Geoscope Technologies Pte. Ltd.'s patents related to ...

27. Case: Patents/Obviousness (P.T.A.B.) - Bloomberg Law News

Case: Patents/Obviousness (P.T.A.B.) ... Challenged claims of Cleveland Medical Devices Inc.'s patent that relates to devices and methods for sleep ...

28. UK Court of Appeal orders Apple to pay Optis more money in FRAND dispute - JUVE Patent

Texas-based Optis Cellular Technology sued Apple in London in 2019 over its use of eight patents which Optis claims are essential to certain ...

29. Trusted Supply World-First Technology – Seoul Semiconductor at LFI 2025 - Business Wire

Since its founding, Seoul Semiconductor has consistently reinvested approximately 10% of its annual revenue into R&D, resulting in over 18,000 patents ...

30. Alpha Modus Reaches Settlement Agreement with Kroger in Patent Litigation - Stock Titan

The lawsuit centered on alleged infringement of Alpha Modus's patents for intelligent retail display systems. The litigation has been dismissed ...

31. [Podcast] A New Test: Landmark Decision Overrules Framework for Design Patent Obviousness

... patents, sending BakerHostetler attorneys into overdrive as they guide patent owners and challengers in how to obtain and enforce design patents ...

32. Canon Files New Patents for Wide-Angle Prime and Zoom Lenses - The Phoblographer

Canon has filed new patents that showcase new designs for wide angle lenses. Here's what you can expect from them.

33. HMD withdraws EU antitrust complaint over 4G SEP in VoiceAge dispute | MLex

... Patents on fair, reasonable and non-discriminatory, or Frand, terms (see here). HMD's initial complaint came amid mounting litigation worldwide ...

34. Firefly Neuroscience Acquires Evoke To Expand Brain Data, Patents, And Commercial Reach

... patents, and over 60 active commercial users. These represent more than two-fold, three-fold, and ten-fold increases, respectively, compared to ...

35. RDF/XML alternative version - Legislation.gov.uk

... Patents Act 1988 Part III Chapter III in force on 1st February 1991 start=1991-02-01; Copyright, Designs and Patents Act 1988 Part III Chapter III ...